Ballast Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ballast Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22	Closed	-$4.16K	–	294
2026 Q1	$4.16K	Buy	+22	New	+$3.85K	﹤0.01%	342

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ballast Advisors's JAZZ Position: Q2 2026 in Review

Ballast Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 22 shares — an estimated $4.16K sold.

Ballast Advisors first reported a position in JAZZ in Q1 2026 and held it in 1 quarter. The position peaked at $4.16K in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Ballast Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ballast Advisors sold 22 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.16K.
Ballast Advisors first reported a position in Jazz Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Ballast Advisors's Jazz Pharmaceuticals position peaked at $4.16K in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ballast Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.